$AQST

Aquestive Therapeutics ($AQST) investors have until May 4, 2026 to join a securities fraud lawsuit alleging the company concealed human factors issues with its Anaphylm sublingual film product.

Class action lawsuit filed against $ATARA alleging securities fraud over false statements regarding manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.

Class action lawsuit filed against Aquestive Therapeutics after company failed to disclose FDA deficiencies blocking Anaphylm approval, triggering 37% stock decline.

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly misleading investors about Anaphylm drug approval prospects, citing undisclosed FDA deficiencies.

Class action lawsuit filed against $AQST alleging securities fraud over false FDA timeline statements and concealed safety risks for Anaphylm drug.

Rosen Law Firm urges Aquestive Therapeutics investors with $100K+ losses to secure counsel before May 4 deadline in ongoing securities class action alleging false statements and disclosure failures.

Class action lawsuit filed against $AQST alleging executives made false statements about Anaphylm FDA approval timeline and concealed human factors risks.

Pomerantz Law Firm filed securities fraud lawsuit against $AQST after FDA rejected Anaphylm NDA, triggering 37% stock drop. Investor deadline May 4.

Eos Energy stock plummeted 39.44% after missing earnings targets due to production and quality control issues, prompting Pomerantz Law Firm to file securities fraud class action lawsuit.

Rosen Law Firm alerts AQST investors of May 4, 2026 deadline to join class action alleging Aquestive Therapeutics concealed human factors issues with its Anaphylm drug application.

Aquestive Therapeutics faces securities lawsuit after FDA Anaphylm deficiency notice triggers 37% stock decline from $6.21 to $3.91 on January 9, 2026.

Aquestive Therapeutics faces class action lawsuit alleging securities fraud over false FDA approval statements and concealed anaphylaxis product risks.

Aquestive Therapeutics faces class action lawsuit alleging FDA approval misrepresentations for Anaphylm. Stock dropped 37% January 9; lead plaintiff applications due May 4, 2026.

Rosen Law Firm urges Aquestive Therapeutics investors to secure legal counsel before deadlines in securities class action alleging false product and disclosure statements.

Rosen Law Firm files securities class action against Franklin BSP Realty Trust ($FBRT) over alleged misstatements on dividends; April 2026 deadline for lead plaintiff participation.

Law firm announces lead plaintiff deadlines for shareholder class actions against $AQST, $NKTR, and $EOSE over alleged false statements and misleading guidance.

Aquestive Therapeutics faces securities fraud lawsuit after 37% stock drop tied to undisclosed FDA deficiencies in Anaphylm NDA. Lead plaintiff recruitment deadline: May 4, 2026.

Class action lawsuit filed against Aquestive Therapeutics alleging securities fraud related to Anaphylm FDA approval timeline and undisclosed human factors risks.

Rosen Law Firm files securities class action against Franklin BSP Realty Trust, alleging management made false statements about business prospects and finances.

Rosen Law Firm files class action against Aquestive Therapeutics for allegedly concealing human factors issues in Anaphylm NDA. Investors have until May 4, 2026 deadline.